Newsroom
Newsroom
Industry News
Led by Viking Global Investors, the Series B round will be used to bring Antheia's first pharmaceutical compounds to market, expand its pipeline and scale...
Industry News
Menlo Park, California-based Antheia, a synthetic biology company, has raised $73 million in Series B financing. Viking Global Investors led the round with participation from...
Industry News
Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, has raised $73 million in Series B financing....
Industry News
Antheia has raised $73 million to support the commercialization of its first pharmaceutical compound and the scale-up of production of active pharmaceutical ingredients and key...
Industry News
Company's SynBio platform enables manufacturing of complex plant-based drugs Biomanufacturing and synthetic biology (SynBio) manufacturing platforms have the potential to create more resilient supply chains...
Industry News
An expert from synthetic biology tech firm Antheia offers ways to rethink current sourcing and manufacturing strategies to tackle current and future woes......
Blog Posts
Since launching Antheia in 2015, we’ve made tremendous strides toward our mission to transform pharmaceutical supply chains for essential medicines. We’ve strengthened our leadership team...
Industry News
Antheia was a proud sponsor of this year's Global Synthetic Biology Conference, and participated in two high impact talks designed to share our progress toward...
Industry News
Led by Viking Global Investors, the Series B round will be used to bring Antheia's first pharmaceutical compounds to market, expand its pipeline and scale...
Industry News
Menlo Park, California-based Antheia, a synthetic biology company, has raised $73 million in Series B financing. Viking Global Investors led the round with participation from...
Industry News
Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, has raised $73 million in Series B financing....
Industry News
Antheia has raised $73 million to support the commercialization of its first pharmaceutical compound and the scale-up of production of active pharmaceutical ingredients and key...
Industry News
Company's SynBio platform enables manufacturing of complex plant-based drugs Biomanufacturing and synthetic biology (SynBio) manufacturing platforms have the potential to create more resilient supply chains...
Industry News
An expert from synthetic biology tech firm Antheia offers ways to rethink current sourcing and manufacturing strategies to tackle current and future woes......
Blog Posts
As a part of our new “Meet the Team” series, we hear from Ken Takeoka, Antheia’s very first employee and a Scientist III. Read on...
Blog Posts
It’s a momentous day for my research team at Stanford University. Today, we’ve announced a new paper published in Nature that describes the first successful...
Blog Posts
Over the last 150 years, the pharmaceutical industry has focused on decoupling the production of medicinal compounds from their sources in the natural world, which...
Blog Posts
We started Antheia four years ago with a steadfast commitment to help build a more robust drug supply chain – one that delivers the right...
Blog Posts
mericans spend over $300 billion on pharmaceutical drugs every year. In normal times, the supply chain behind these drugs is designed to go unnoticed......
Blog Posts
For thousands of years, communities across cultures and geographies have relied on the inherent healing properties of plants. Ancient Greek physicians prized mint for treating...